289 related articles for article (PubMed ID: 26549523)
1. An EGFR/Src-dependent β4 integrin/FAK complex contributes to malignancy of breast cancer.
Tai YL; Chu PY; Lai IR; Wang MY; Tseng HY; Guan JL; Liou JY; Shen TL
Sci Rep; 2015 Nov; 5():16408. PubMed ID: 26549523
[TBL] [Abstract][Full Text] [Related]
2. TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Golubovskaya VM; Virnig C; Cance WG
Mol Carcinog; 2008 Mar; 47(3):222-34. PubMed ID: 17849451
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma.
Madan R; Smolkin MB; Cocker R; Fayyad R; Oktay MH
Hum Pathol; 2006 Jan; 37(1):9-15. PubMed ID: 16360410
[TBL] [Abstract][Full Text] [Related]
4. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth.
Bertotti A; Comoglio PM; Trusolino L
J Cell Biol; 2006 Dec; 175(6):993-1003. PubMed ID: 17158954
[TBL] [Abstract][Full Text] [Related]
5. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway.
Leng C; Zhang ZG; Chen WX; Luo HP; Song J; Dong W; Zhu XR; Chen XP; Liang HF; Zhang BX
Cancer Lett; 2016 Jun; 376(1):188-96. PubMed ID: 26996299
[TBL] [Abstract][Full Text] [Related]
6. Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells.
Park HB; Golubovskaya V; Xu L; Yang X; Lee JW; Scully S; Craven RJ; Cance WG
Biochem J; 2004 Mar; 378(Pt 2):559-67. PubMed ID: 14629195
[TBL] [Abstract][Full Text] [Related]
7. Activation of focal adhesion kinase through an interaction with β4 integrin contributes to tumorigenicity of colon cancer.
Tai YL; Lai IR; Peng YJ; Ding ST; Shen TL
FEBS Lett; 2016 Jun; 590(12):1826-37. PubMed ID: 27178753
[TBL] [Abstract][Full Text] [Related]
8. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
10. Src and FAK mediate cell-matrix adhesion-dependent activation of Met during transformation of breast epithelial cells.
Hui AY; Meens JA; Schick C; Organ SL; Qiao H; Tremblay EA; Schaeffer E; Uniyal S; Chan BM; Elliott BE
J Cell Biochem; 2009 Aug; 107(6):1168-81. PubMed ID: 19533669
[TBL] [Abstract][Full Text] [Related]
11. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
Bertotti A; Comoglio PM; Trusolino L
Cancer Res; 2005 Dec; 65(23):10674-9. PubMed ID: 16322210
[TBL] [Abstract][Full Text] [Related]
12. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer.
Planas-Silva MD; Bruggeman RD; Grenko RT; Stanley Smith J
Biochem Biophys Res Commun; 2006 Mar; 341(1):73-81. PubMed ID: 16412380
[TBL] [Abstract][Full Text] [Related]
13. Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src.
Hsia DA; Lim ST; Bernard-Trifilo JA; Mitra SK; Tanaka S; den Hertog J; Streblow DN; Ilic D; Ginsberg MH; Schlaepfer DD
Mol Cell Biol; 2005 Nov; 25(21):9700-12. PubMed ID: 16227616
[TBL] [Abstract][Full Text] [Related]
14. MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling.
Lakshmanan I; Rachagani S; Hauke R; Krishn SR; Paknikar S; Seshacharyulu P; Karmakar S; Nimmakayala RK; Kaushik G; Johansson SL; Carey GB; Ponnusamy MP; Kaur S; Batra SK; Ganti AK
Oncogene; 2016 Aug; 35(31):4112-21. PubMed ID: 26751774
[TBL] [Abstract][Full Text] [Related]
15. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling.
Wang K; Zou P; Zhu X; Zhang T
Toxicol In Vitro; 2019 Dec; 61():104653. PubMed ID: 31525383
[TBL] [Abstract][Full Text] [Related]
16. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD
Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415
[TBL] [Abstract][Full Text] [Related]
17. UNC5C‑knockdown enhances the growth and metastasis of breast cancer cells by potentiating the integrin α6/β4 signaling pathway.
Yuan M; Xie F; Xia X; Zhong K; Lian L; Zhang S; Yuan L; Ye J
Int J Oncol; 2020 Jan; 56(1):139-150. PubMed ID: 31789389
[TBL] [Abstract][Full Text] [Related]
18. Clonorchis sinensis excretory-secretory products promote the migration and invasion of cholangiocarcinoma cells by activating the integrin β4-FAK/Src signaling pathway.
Pak JH; Bashir Q; Kim IK; Hong SJ; Maeng S; Bahk YY; Kim TS
Mol Biochem Parasitol; 2017 Jun; 214():1-9. PubMed ID: 28286026
[TBL] [Abstract][Full Text] [Related]
19. Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast Cancer.
Evans R; Flores-Borja F; Nassiri S; Miranda E; Lawler K; Grigoriadis A; Monypenny J; Gillet C; Owen J; Gordon P; Male V; Cheung A; Noor F; Barber P; Marlow R; Francesch-Domenech E; Fruhwirth G; Squadrito M; Vojnovic B; Tutt A; Festy F; De Palma M; Ng T
Cell Rep; 2019 May; 27(7):1967-1978.e4. PubMed ID: 31091437
[TBL] [Abstract][Full Text] [Related]
20. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
